IP Verse

Treatment Of Lung Cancer Using A Combination Of An Anti-Pd-1 Antibody And An Anti-Ctla-4 Antibody

Patent No. EP3377534 (titled "Treatment Of Lung Cancer Using A Combination Of An Anti-Pd-1 Antibody And An Anti-Ctla-4 Antibody") was filed by Bristol Myers Squibb on Nov 18, 2016. The application was issued on Jun 18, 2025.

Patent Summary

Patent Family

Patent Family

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
POHLMANMar 18, 2026POHLMAN
PAJAROMar 17, 2026BIRD & BIRD
DEVA HOLDINGMar 11, 2026-

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3377534

BRISTOL MYERS SQUIBB
Application Number
EP16819718A
Filing Date
Nov 18, 2016
Status
Granted And Under Opposition
May 16, 2025
Publication Date
Jun 18, 2025
External Links
Slate, Register , Google Patents